Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver dis

• 作 者: Ye Liu Rui Wei Tian-Pei Hong
• 机 构: DepartmentofEndocrinologyMetabolism
• 出 处: 世界胃肠病学杂志：英文版（电子版）
• 发表日期: 2014年27期
• 关键词: Non-alcoholic FATTY LIVER disease Glucagonlike PEP Non-alcoholic fatty liver dis
• 基金项目: Chinese National 973 Program No.2012CB517502,the Research Fund for the Doctoral Program of Higher Education of China No.20120001120069

Glucagon-like peptide-1(GLP-1)-based therapies have demonstrated efficacy and safety in treating type 2 diabetes, which shares a similar pathophysiological mechanism with non-alcoholic fatty liver disease(NAFLD). Recent studies showed that glucose-induced